Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701).

被引：3

作者：

LaPointe, Nichole

Hertle, Nick

Hsu, Shu Chi

Kellis, James

King, Nita

Littrell, Joshua

Quyen Nguyen

Ren, Jianan

Srdanov, Marko Romeo

Tanna, Vaishali

Thakrar, Sanchit

Zhao, Tianxun

Saiz, Robert

Le Bail, Nathalie

Bauchet, Anne-Laure

Lacoste-Bourgeacq, Anne-Sophie

Chadjaa, Mustapha

Ferrari, Paul

机构：

[1] Agilent, Carpinteria, CA USA

[2] Sanofi, Cambridge, MA USA

[3] Sanofi, Vitry Sur Seine, France

[4] Sanofi, Chilly Mazarin, France

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e21030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21030

引用

页数：3